-
公开(公告)号:US20130089625A1
公开(公告)日:2013-04-11
申请号:US13631732
申请日:2012-09-28
申请人: Jean-Damien Charrier , Pierre-Henri Storck , John Studley , Francoise Yvonne Theodora Marie Pierard , Steven John Durrant , Benjamin Joseph Littler , Paul Angell , Robert Michael Hughes , David Andrew Siesel , Armando Urbina , Carl Zwicker , Nicholas LoConte , Timothy Barder
发明人: Jean-Damien Charrier , Pierre-Henri Storck , John Studley , Francoise Yvonne Theodora Marie Pierard , Steven John Durrant , Benjamin Joseph Littler , Paul Angell , Robert Michael Hughes , David Andrew Siesel , Armando Urbina , Carl Zwicker , Nicholas LoConte , Timothy Barder
IPC分类号: C07D413/14 , A61K45/06 , A61N5/10 , A61K31/4745 , A61K31/7068 , A61K31/497 , A61K33/24
CPC分类号: C07D413/14 , A61K31/4745 , A61K31/497 , A61K31/7068 , A61K33/24 , A61K45/06 , A61N5/10
摘要: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; solid forms of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula I-1: wherein the variables are as defined herein.Additionally, the compounds of this invention have formula II: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein.
摘要翻译: 本发明涉及可用作ATR蛋白激酶抑制剂的化合物。 本发明还涉及包含本发明化合物的药学上可接受的组合物; 使用本发明化合物治疗各种疾病,病症和病症的方法; 制备本发明化合物的方法; 用于制备本发明化合物的中间体; 固体形式的本发明化合物; 以及在体外应用中使用化合物的方法,如生物和病理现象中激酶的研究; 由这种激酶介导的细胞内信号转导途径的研究; 和新型激酶抑制剂的比较评估。 本发明的化合物具有式I-1:其中变量如本文所定义。 此外,本发明的化合物具有式II:或其药学上可接受的盐,其中变量如本文所定义。